Congruence Therapeutics
Indranath Ghosh is a highly experienced medicinal chemist who has held various significant roles in different pharmaceutical companies. Ghosh has a strong background in designing and synthesizing novel compounds for various therapeutic programs, including CD33 glycomimetic drug conjugates, Galectin-3 inhibitors, and orally available E-selectin antagonists. With a Ph.D. in Synthetic Organic Chemistry from Dartmouth College and postdoctoral research fellowship from Harvard University, Ghosh has a solid educational foundation to support their successful career in drug discovery and development.
This person is not in any offices
Congruence Therapeutics
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.